Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | MTTP | P55157 | 4/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832646 | 1.00 | SLC6A9 (0.52) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| SCHEMBL3014546 | 1.00 | SLC6A9 (0.52) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| SCHEMBL29765315 | 1.00 | SLC6A9 (0.52) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| SCHEMBL3239910 | 0.99 | SLC6A9 (0.51) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| SCHEMBL3243383 | 0.99 | SLC6A9 (0.51) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| Hydrochloric Acid SCHEMBL3243468 | 0.99 | SLC6A9 (0.51) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| Succinic Acid SCHEMBL3836544 | 0.96 | SLC6A9 (0.49) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| Succinic Acid SCHEMBL3831049 | 0.96 | SLC6A9 (0.49) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| Succinic Acid SCHEMBL3830489 | 0.96 | SLC6A9 (0.49) | SLC6A9CYP2D6CYP2C19SLC6A5MTTP | |
| SCHEMBL3238676 | 0.90 | SLC6A9 (0.44) | SLC6A9TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | claimed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | claimed |
| EP-2041082-B1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LTD (GB) | 2009-09-30 | — | — | EP | claimed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | claimed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11117868-B2 | Edaravone salt | TREEWAY TW001 B.V. (NL) | 2021-09-14 | — | — | US | disclosed |
| US-20200308120-A1 | EDARAVONE SALT | TREEWAY TW001 B.V. (NL) | 2020-10-01 | — | — | US | disclosed |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | ADH1C, ADH5, ADH1A | SLC6A9 2553/4885CYP2D6 1196/4885CYP2C19 3090/4885 |
| US-20200308120-A1 | EDARAVONE SALT | SYMPK, EDNRA, NEK5 | SLC6A9 1281/4885CYP2D6 263/4885CYP2C19 423/4885 |
| US-11117868-B2 | Edaravone salt | SYMPK, EDNRA, NEK5 | SLC6A9 1281/4885CYP2D6 263/4885CYP2C19 423/4885 |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885CYP2D6 739/4885CYP2C19 771/4885 |
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885CYP2D6 443/4885CYP2C19 623/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885CYP2D6 739/4885CYP2C19 771/4885 |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | SLC6A7, SLC6A1, SLC6A4 | SLC6A9 27/4885CYP2D6 311/4885CYP2C19 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.